Penicillin V, loracarbef and clindamycin in tonsillar surface fluid during acute group A streptococcal pharyngotonsillitis

Scandinavian Journal of Infectious Diseases

Volumn 37, Issue 6-7, 2005, Pages 429-435

  Orrling, Arne ^a   Kamme, Carl ^a   Stjernquist Desatnik, Anna ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CLINDAMYCIN; DNA; LORACARBEF; OROSOMUCOID; PENICILLIN V POTASSIUM;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA FINGERPRINTING; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG SALIVA LEVEL; EPITHELIUM CELL; FEMALE; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; PHARYNGITIS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RESPIRATORY EPITHELIUM; STREPTOCOCCUS GROUP A; TONSILLITIS; TREATMENT FAILURE;

ADULT; AGED; ANTI-BACTERIAL AGENTS; C-REACTIVE PROTEIN; CEPHALOSPORINS; CLINDAMYCIN; FEMALE; HUMANS; MALE; MIDDLE AGED; OROSOMUCOID; PENICILLIN V; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES; TISSUE DISTRIBUTION; TONSIL; TONSILLITIS;

EID: 22844440601     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.1080/00365540410020947     Document Type: Article

References (32)

1. Stjernquist-Desamik A, Prellner K, Christensen P. Clinical and laboratory findings in patients with acute tonsillitis. Acta Otolaryngol (Stockholm) 1987;104:351-9.
2. Schwartz R, Wientzen R, Pedreira F, Feroli EJ, Mella GW, Guandolo UL. Penicillin V for group A streptococcal pharyngotonsillitis. JAMA 1981;246:1790-5.
3. Orrling A, Stjernquist-Desatnik A, Schalén C, Kamme C. Clindamycin in persisting streptococcal pharyngotonsillitis after penicillin treatment. Scand J Infect Dis 1994;26:535-41.
4. Orrling A, Stjernquist-Desatnik A, Schalén C. Clindamycin in recurrent group A streptococcal pharyngotonsillitis: an alternative to tonsillectomy? Acta Otolaryngol (Stockholm) 1997;117:618-22.
5. Kaplan EL, Johnson DR. Clinical and laboratory observations: eradication of group A streptococci from the upper respiratory tract by amoxicillin with clavulanate after oral penicillin V treatment failure. The Journal of Pediatrics 1988;113:400-3.
6. Brook I. Role of beta-lactamase-producing bacteria in the failure of penicillin to eradicate group A streptococci. Pediatr Infect Dis 1985;4:491-5.
7. Pichichero ME, Disney FA, Aronovitz GH, Talpey WB, Green JL, Francis AB. Randomized, single-blind evaluation of cefadroxil and phenoxymethyl penicillin in the treatment of streptococcal pharyngitis. Antimicrobial Agents and Chemotherapy 1987;31:903-6.
8. Sanders C, Sanders E, Harrow D. Bacterial interference: effects of oral antibiotics on the normal throat flora and their ability to interfere with a group A streptococci. Infect Immun 1976;13:808-12.
9. Roos K, Grahn E, Holm SE, Johansson H, Lind L. Interfering alpha-streptococci as a protection against recurrent streptococcal tonsillitis in children. Int J Pediatr Otorhinolaryngol 1993;25:141-8.
10. Kim KS, Kaplan EL. Association of penicillin tolerance with failure to eradicate group A streptococci from patients with pharyngitis. J Pediatr 1985;107:681-4.
11. Orrling A, Stjernquist-Desatnik A, Schalén C, Kamme C. Treatment failure in streptococcal pharyngotonsillitis. An attempt to identify penicillin tolerant Streptococcus pyogenes. Scand J Infect Dis 1996;28:143-7.
12. La Penta D, Rubens C, Chi E, Cleary P. Group A streptococci efficiently invade human respiratory epithelial cells. Proc Natl Acad Sci USA 1994;91:12115-9.
13. Österlund A, Popa R, Nikkilä T, Scheynius A, Engstrand L. Intracellular reservoir of Streptococcus pyogenes in vivo: a possible explanation for recurrent pharyngotonsillitis. The Laryngoscope 1997;107:640-7.
14. Österlund A, Engstrand L. An intracellular sanctuary for Streptococcus pyogenes in human tonsillar epithelium: studies of asymptomatic carriers and in vitro cultured biopsies. Acta Otolaryngol (Stockholm) 1997;117:883-8.
15. Österlund A, Engstrand L. DNA fingerprinting of Streptococcus pyogenes from patients with recurrent pharyngotonsillitis by means of random amplified polymorphic DNA analysis. Scand J Infect Dis 1995;27:119-21.
16. Orrling A, Melhus Å, Karlsson E, Stjernquist-Desatnik A. Penicillin treatment failure in group A streptococcal tonsillopharyngitis: no genetic difference found between strains isolated from failures and non-failures. Annals of Otology. Rhinology & Laryngology 2001;110:690-5.
17. Ebenfelt A, Lundberg C. Bacterial invasion of the tonsillar tissues in acute pharyngotonsillitis and in the adenoid: a preliminary study. Clin Otolaryngol 1994;19:310-3.
18. Strömberg A, Friberg U, Cars O. Concentrations of phenoxymethylpenicillin and cefadroxil in tonsillar tissue and tonsinar surface fluid. European Journal of Clinical Microbiology 1987;6:525-9.
19. Stjernquist-Desatnik A, Samuelsson P, Walder M. Penetration of penicillin V tonsillar surface fluid in healthy individuals and in patients with acute tonsillitis. Laryngol Otol 1993;107:309-12.
20. Jensen JH, Larsen SB. Treatment of recurrent acute tonsillitis with clindamycin: an alternative to tonsillectomy? Clin Otolaryngol 1991;16:498-500.
21. Price CP, Spencer K, Whicher J. Light scattering immunoassay of specific proteins: a review. Ann Clin Biochem 1983;20:1-14.
22. Svendsen PJ, Blirup-Jensen S. Determination of human plasma proteins by turbidimetry and nephelometry. Copenhagen: Dako; 1991.
23. Kamme C, Petersson A-C. In vitro effect on group A streptococci of loracarbef versus cefadroxil, cefaclor and penicillin V. Scand J Infect Dis 1993;25:37-42.
24. Kataja J, Huovinen P, Skurnik M, The Finnish study group for antimicrobial resistance, Seppälä H. Erythromycin resistance genes in group A streptococci in Finland. Antimicrobial Agents and Chemotherapy 1999;43:48-52.
25. Cohen R, Reinert P, De La Rocque F, Levy C, Boucherat M, Robert M, et al. Comparison of 2 dosages of azithromycin for 3 d vs penicillin V for 10 d in acute group A streptococcal tonsillopharyngitis. Pediatr Infect Dis J 2002;21:297-303.
26. Brook I, Hirokawa R. Treatment of patients with a history of recurrent tonsillitis due to group A beta-haemolytic streptococci. Clinical Pediatrics 1985;24:331-6.
27. Watkins VS, Smietana M, Conforti PM, Sides GD, Huck W. Comparison of dirithromycin and penicillin for treatment of streptococcal pharyngitis. Antimicrobial Agents and Chemotherapy 1997;41:72-5.
28. Strömberg A, Schwan A, Cars O. Five versus 10 d treatment of group A streptococcal pharyngotonsillitis randomized controlled clinical trial with phenoxymethylpenicillin and cefadroxil. Scand J Infect Dis 1988;20:37-46.
29. Roos K, Larsson P. Loracarbef versus phenoxymethylpenicillin in the treatment of recurrent streptococcal pharyngotonsillitis. Scand J Infect Dis 1997;29:141-5.
30. Tulkens PM. Intracellular pharmacokinetics and localization of antibiotics as predictors of their efficacy against intraphagocytic infections. Scand J Infect Dis Suppl 1991;74:209-17.
31. Eli Lilly & Co. MSDS: Loracarbef monohydrate.
32. Stevens D, Gibbons A, Bergström R, Winn V. The Eagle effect revisited: efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. J Infect Dis 1988;158:23-8.